Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF-21101(90Y) in advanced solid tumors
NCT02454010Phase 1Completed
- Sponsor
- Fujifilm Pharmaceuticals
- Start
- Jan 2016
- Primary completion
- Oct 2021
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of FF-21101 (90Y) in solid tumor, ovarian cancer, triple-negative breast cancer (TNBC) and 5 more (7 arms), sponsored by Fujifilm Pharmaceuticals. Primary endpoint: Safety and tolerability of radio-labeled FF21101 at 28 days. Started Jan 2016; status: completed.
02
Drugs
FF-21101 (90Y)
03
Conditions
solid tumorovarian cancertriple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02454010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454010.